Safety, efficacy, and tolerabilit…lled, phase 3 trial.
🔬 Peer-reviewed
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S et al.
The Lancet. Neurology · 2021
Findings
PubMed study on Mannan in cosmetics/dermatology
Design
Randomized Controlled Trial
Evidence
Moderate
Journal
The Lancet. Neurology
Ingredients studied